|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 February 2001, Vol. 97, No. 4, pp. 1050-1055
NEOPLASIA
Constitutive kinase activation of the TEL-Syk fusion
gene in myelodysplastic syndrome with t(9;12)(q22;p12)
Yoshie Kuno,
Akihiro Abe,
Nobuhiko Emi,
Minako Iida,
Toshiya Yokozawa,
Masayuki Towatari,
Mitsune Tanimoto, and
Hidehiko Saito
From the First Department of Internal Medicine, Nagoya
University School of Medicine, Nagoya, Japan.
The TEL gene on 12p12-13 is a target for a number of
translocations associated with various hematological malignancies.
The fusion of the TEL gene to the Syk
gene in a patient with myelodysplastic syndrome (MDS) with
t(9;12)(q22;p12) is reported. Southern blot analysis of patient bone
marrow cells with TEL and Syk gene probes detected rearranged fragments. Anchored polymerase chain reaction identified the Syk gene, a nonreceptor tyrosine kinase, on
9q22 fused downstream of TEL exon 5. The TEL
gene was fused in-frame to Syk and produced a fusion
protein that was constitutively phosphorylated in tyrosine with
dimerization that was mediated by the helix-loop-helix domain
of TEL. A TEL-Syk fusion product transformed
the murine hematopoietic cell line BaF3 to interleukin-3 growth factor
independence. TEL-Syk is a novel transforming protein and leads to the
transformation of hematopoietic cells. These data implicate that the
rearranged Syk gene is involved in the pathogenesis of
hematopoietic malignancies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Rigby, Y. Huang, B. Streubel, A. Chott, M.-Q. Du, S. D. Turner, and C. M. Bacon
The Lymphoma-associated Fusion Tyrosine Kinase ITK-SYK Requires Pleckstrin Homology Domain-mediated Membrane Localization for Activation and Cellular Transformation
J. Biol. Chem.,
September 25, 2009;
284(39):
26871 - 26881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Buchner, S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholome, M. Burger, N. Chevalier, L. Vallat, J. Timmer, J. G. Gribben, et al.
Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
Cancer Res.,
July 1, 2009;
69(13):
5424 - 5432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shannon and L. R. Silverman
Myelodysplastic syndrome and overlap syndromes
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
228 - 242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Wossning, S. Herzog, F. Kohler, S. Meixlsperger, Y. Kulathu, G. Mittler, A. Abe, U. Fuchs, A. Borkhardt, and H. Jumaa
Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells
J. Exp. Med.,
December 25, 2006;
203(13):
2829 - 2840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Nakamura, Y. Nakamura, K. Maki, Y. Sato, and K. Mitani
Cloning and Characterization of the Novel Chimeric Gene TEL/PTPRR in Acute Myelogenous Leukemia with inv(12)(p13q13)
Cancer Res.,
August 1, 2005;
65(15):
6612 - 6621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Krause and R. A. Van Etten
Tyrosine Kinases as Targets for Cancer Therapy
N. Engl. J. Med.,
July 14, 2005;
353(2):
172 - 187.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Moon, C. B. Post, D. L. Durden, Q. Zhou, P. De, M. L. Harrison, and R. L. Geahlen
Molecular Basis for a Direct Interaction between the Syk Protein-tyrosine Kinase and Phosphoinositide 3-Kinase
J. Biol. Chem.,
January 14, 2005;
280(2):
1543 - 1551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Maki, H. Arai, K. Waga, K. Sasaki, F. Nakamura, Y. Imai, M. Kurokawa, H. Hirai, and K. Mitani
Leukemia-Related Transcription Factor TEL Is Negatively Regulated through Extracellular Signal-Regulated Kinase-Induced Phosphorylation
Mol. Cell. Biol.,
April 15, 2004;
24(8):
3227 - 3237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cools, N. Mentens, M. D. Odero, P. Peeters, I. Wlodarska, M. Delforge, A. Hagemeijer, and P. Marynen
Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)
Blood,
March 1, 2002;
99(5):
1776 - 1784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Yagasaki, D. Wakao, Y. Yokoyama, Y. Uchida, I. Murohashi, H. Kayano, M. Taniwaki, A. Matsuda, and M. Bessho
Fusion of ETV6 to Fibroblast Growth Factor Receptor 3 in Peripheral T-Cell Lymphoma with a t(4;12)(p16;p13) Chromosomal Translocation
Cancer Res.,
December 1, 2001;
61(23):
8371 - 8374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
